Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ifosfamide in pediatric solid tumors.

M Carli1, E Passone, G Perilongo

  • 1Division of Haematology-Oncology, Department of Pediatrics, University Hospital, Padova, Italy. modesto.carli@unipd.it

Oncology
|October 31, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Administration of Samital® in children with oral mucositis: a feasibility study.

European review for medical and pharmacological sciences·2022
Same author

In transit metastases in children, adolescents and young adults with localized rhabdomyosarcoma of the distal extremities: Analysis of the EpSSG RMS 2005 study.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2022
Same author

Cross-cutting view of current challenges in paediatric solid organ and haematopoietic stem cell transplantation in Europe: the European Reference Network TransplantChild.

Orphanet journal of rare diseases·2020
Same author

Inequalities in diagnosis and registration of pediatric very rare tumors: a European study on pleuropulmonary blastoma.

European journal of pediatrics·2020
Same author

High dose chemotherapy and autologous hematopoietic cell transplantation for Wilms tumor: a study of the European Society for Blood and Marrow Transplantation.

Bone marrow transplantation·2019
Same author

The quality of life in extracorporeal life support survivors: single-center experience of a long-term follow-up.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery·2018
Same journal

SF3A3 in Liver Hepatocellular Carcinoma: Oncogenic Role and Prognostic Significance.

Oncology·2026
Same journal

Letter to the Editor.

Oncology·2026
Same journal

FLAG-Based Versus Standard 7+3 Induction Therapy in Adults with Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.

Oncology·2026
Same journal

Longitudinal Changes in Body Weight and Body Mass Index in Patients with Chronic-Phase Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: A Retrospective Observational Study.

Oncology·2026
Same journal

Rising lung cancer burden attributable to high fasting plasma glucose in women aged ≥50 years: age-, SDI-, and BRICS-specific patterns from GBD 1990-2021.

Oncology·2026
Same journal

Diagnostic Pathways and Outcomes of First-Line Atezolizumab plus Bevacizumab in Patients with Locoregional Therapy-Ineligible Hepatocellular Carcinoma at Initial Diagnosis.

Oncology·2026
See all related articles

Ifosfamide is an active chemotherapy drug for pediatric solid tumors like rhabdomyosarcoma and bone sarcomas. It shows increased efficacy in combination therapies and is preferred in short infusions to minimize neurotoxicity.

Area of Science:

  • Pediatric Oncology
  • Medical Chemotherapy
  • Pharmacology

Background:

  • Ifosfamide is a chemotherapy agent used in treating various pediatric solid tumors.
  • Phase II studies have established its activity as a single agent and in combination regimens.

Purpose of the Study:

  • To summarize the efficacy and administration of ifosfamide in pediatric solid tumors.
  • To highlight its role in current therapeutic strategies for specific childhood cancers.

Main Methods:

  • Review of Phase II clinical studies conducted in Europe and the USA.
  • Analysis of treatment regimens, dosages, and infusion times.
  • Evaluation of drug activity across different pediatric neoplasms.

Main Results:

Related Experiment Videos

  • Ifosfamide demonstrates activity against rhabdomyosarcoma, soft tissue sarcomas, Wilms' tumor, bone sarcomas, and neuroblastoma.
  • Combination therapy with ifosfamide enhances tumor response rates.
  • Short infusion (3h) is generally preferred over prolonged infusion (24h) due to reduced neurotoxicity.

Conclusions:

  • Ifosfamide is a key component in the standard treatment of pediatric bone and soft tissue sarcomas.
  • It is also utilized in high-risk pediatric patients with Wilms' tumor, neuroblastoma, and germ cell tumors.